Zobrazeno 1 - 10
of 472
pro vyhledávání: '"G, Kohlhagen"'
Autor:
I J Hoogsteen, Marc Maliepaard, Epie Boven, R.J. Scheper, Hennie M.M. Schlüper, A. H. Van Hattum, G Kohlhagen, George L. Scheffer, H.M. Pinedo, Y Pommier
Publikováno v:
British Journal of Cancer
DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the hu
Autor:
M P, Gamcsik, M S, Kasibhatla, D J, Adams, J L, Flowers, O M, Colvin, G, Manikumar, M, Wani, M E, Wall, G, Kohlhagen, Y, Pommier
Publikováno v:
Molecular cancer therapeutics. 1(1)
Depletion of glutathione (GSH) in MCF-7 and MDA-MB-231 cell lines by pretreatment with the GSH synthesis inhibitor buthionine sulfoximine potentiated the activity of 10,11-methylenedioxy-20(S)-camptothecin, SN-38 [7-ethyl-10-hydroxy-20(S)-camptotheci
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(1)
Ecteinascidin 743 (Et743; NSC 648766) is a potent antitumor agent presently in clinical trials. Et743 selectively alkylates guanine N2 from the minor groove of duplex DNA and bends the DNA toward the major groove. This differentiates Et743 from other
Publikováno v:
Cancer research. 61(2)
NB-506 is a topoisomerase I (top1) inhibitor in clinical trials. In this study, we used a series of camptothecin (CPT)-resistant cell lines with known top1 alterations. We show that three mutations in different domains of the top1 enzyme that confer
Autor:
M, Brangi, T, Litman, M, Ciotti, K, Nishiyama, G, Kohlhagen, C, Takimoto, R, Robey, Y, Pommier, T, Fojo, S E, Bates
Publikováno v:
Cancer research. 59(23)
The mitoxantrone resistance (MXR) gene encodes a recently characterized ATP-binding cassette half-transporter that confers multidrug resistance. We studied resistance to the camptothecins in two sublines expressing high levels of MXR: S1-M1-80 cells
Autor:
H.-M. Koo, M. Gray-Goodrich, G. Kohlhagen, M. J. McWilliams, M. Jeffers, A. Vaigro-Wolff, W. G. Alvord, A. Monks, K. D. Paull, Y. Pommier, G. F. Vande Woude
Publikováno v:
Journal of the National Cancer Institute. 91(3)
Among the inhibitors of the enzyme topoisomerase II (an important target for chemotherapeutic drugs) tested in the National Cancer Institute's In Vitro Antineoplastic Drug Screen, NSC 284682 (3'-hydroxydaunorubicin) and NSC 659687 [9-hydroxy-5,6-dime
Publikováno v:
The Journal of biological chemistry. 272(42)
We used purified mammalian topoisomerases I (top1) and oligonucleotides containing a unique top1 cleavage site to study top1-mediated cleavage and recombination in the presence of nicks and short gaps mimicking DNA damage. In general, top1 cleavage w
Publikováno v:
Molecular pharmacology. 48(4)
A compound with a novel structure, NSC 665517, was tested in the National Cancer Institute Preclinical Drug Discovery Screen. With the COMPARE algorithm, the pattern of differential cytotoxicity for NSC 665517 most closely resembled those of known to
Publikováno v:
Cancer research. 55(6)
We developed previously a resistant cell line, CEM/C2, from the human leukemia cell line CCRF-CEM by stepwise selection in camptothecin. This cell line is 974-fold more resistant to camptothecin than parental cells. Resistance is only partially expla
Autor:
Laboud, Yara N.1 (AUTHOR), Hassaneen, Hamdi M.1 (AUTHOR) hamdi_251@yahoo.com, Hassaneen, Huwaida M. E.1 (AUTHOR), Mohamed Teleb, Mohamed A.1 (AUTHOR), Saleh, Fatma M.1 (AUTHOR)
Publikováno v:
Journal of Heterocyclic Chemistry. Sep2023, Vol. 60 Issue 9, p1565-1571. 7p.